Investor Alert: Pomerantz Law Firm Investigates Emergent BioSolutions for Potential Securities Fraud
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by Emergent BioSolutions Inc. (NYSE: EBS) and its officers or directors on behalf of investors. The investigation follows a significant financial downturn reported in the company's second-quarter results, which included an $180.2 million GAAP net loss driven largely by a $191.3 million non-cash impairment charge related to the NARCAN asset group. Emergent also revised its full-year revenue guidance downward by approximately 10.8% at the midpoint and attributed these results to increased competitive pressure affecting both short- and medium-term outlooks as well as book value of key assets. The news caused Emergent's stock price to drop sharply, falling $2.23 per share (or nearly 30%) on August 6, 2026. Pomerantz LLP is a leading firm in corporate litigation and has previously secured multimillion-dollar damages for class members.
Tickers: $EBS
Topics: corporate_governance investor_protection stock_price_drop